Population pharmacokinetics of ruxolitinib in children with hemophagocytic lymphohistiocytosis: focus on the drug–drug interactions

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies

(2022) Yingxin Zhao et al.   Drug Design Development and Therapy

New Applications of JAK/STAT Inhibitors in Pediatrics: Current Use of Ruxolitinib

(2022) Annalisa Marcuzzi et al.   Pharmaceuticals

Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis

(2021) Camille Keenan et al.   Frontiers in Immunology

Pediatric Hemophagocytic Lymphohistiocytosis (HLH)

(2020) Scott Canna et al.   BLOOD

Hemophagocytic lymphohistiocytosis: An update on pathogenesis, diagnosis, and therapy

(2020) Georgia Griffin et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Ruxolitinib for the treatment of graft-versus-host disease

(2020) Haris Ali et al.   Expert Review of Clinical Immunology

Outcome analysis of pediatric hemophagocytic lymphohistiocytosis

(2020) Tsung-Yen Chen et al.   JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION

Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic Lymphohistiocytosis

(2020) Li Jianguo et al.   PEDIATRICS

Model-Informed Precision Dosing: Background, Requirements, Validation, Implementation, and Forward Trajectory of Individualizing Drug Therapy

(2020) Adam S. Darwich et al.   Annual Review of Pharmacology and Toxicology

Mechanisms of Action of Ruxolitinib in Murine Models of Hemophagocytic Lymphohistiocytosis

(2019) Sabrin Albeituni et al.   BLOOD

Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects

(2019) Vassilios Aslanis et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)

(2019) Michael B. Jordan et al.   PEDIATRIC BLOOD & CANCER

Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis

(2019) Jingshi Wang et al.   HAEMATOLOGICA

Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial

(2019) Asra Ahmed et al.   Lancet Haematology

FDA Approval Summary: Ruxolitinib for Treatment of Steroid‐Refractory Acute Graft‐Versus‐Host Disease

(2019) Donna Przepiorka et al.   ONCOLOGIST

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

(2019) Elena Maria Elli et al.   Frontiers in Oncology

Misconceptions and issues regarding allometric scaling during the drug development process

(2018) Iftekhar Mahmood   Expert Opinion on Drug Metabolism & Toxicology

Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy

(2018) Joshua C. Euteneuer et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hemophagocytic Lymphohistiocytosis: Clinical Presentations and Diagnosis

(2018) Kimberly A. Risma et al.   Journal of Allergy and Clinical Immunology-In Practice

Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis

(2016) R. Das et al.   BLOOD

Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice

(2016) Sophia Maschalidi et al.   BLOOD

Hemophagocytic syndromes (HPSs) including hemophagocytic lymphohistiocytosis (HLH) in adults: A systematic scoping review

(2016) Anna Hayden et al.   BLOOD REVIEWS

Allometry Is a Reasonable Choice in Pediatric Drug Development

(2016) Tao Liu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Hemophagocytic lymphohistiocytosis: Pathogenesis, diagnosis, and management

(2016) Akira Morimoto et al.   PEDIATRICS INTERNATIONAL

Hemophagocytic Lymphohistiocytosis in Children: Pathogenesis and Treatment

(2016) Eiichi Ishii   Frontiers in Pediatrics

A phase 1 dosing study of ruxolitinib in children with relapsed or refractory solid tumors, leukemias, or myeloproliferative neoplasms: A Children's Oncology Group phase 1 consortium study (ADVL1011)

(2015) Mignon L. Loh et al.   PEDIATRIC BLOOD & CANCER

A Population Pharmacokinetic Model of Valproic Acid in Pediatric Patients with Epilepsy: A Non-Linear Pharmacokinetic Model Based on Protein-Binding Saturation

(2014) Junjie Ding et al.   CLINICAL PHARMACOKINETICS

Ruxolitinib for Myelofibrosis–An Update of Its Clinical Effects

(2013) Hagop M. Kantarjian et al.   Clinical Lymphoma Myeloma & Leukemia

Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)

(2013) Xuejun Chen et al.   JOURNAL OF CLINICAL PHARMACOLOGY

A Pharmacokinetic Standard for Babies and Adults

(2013) Nick Holford et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A Bodyweight-Dependent Allometric Exponent for Scaling Clearance Across the Human Life-Span

(2012) Chenguang Wang et al.   PHARMACEUTICAL RESEARCH

Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects Models

(2011) Martin Bergstrand et al.   AAPS Journal

The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers

(2011) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Evaluation of a morphine maturation model for the prediction of morphine clearance in children: how accurate is the predictive performance of the model?

(2010) Iftekhar Mahmood   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans

(2010) A. D. Shilling et al.   DRUG METABOLISM AND DISPOSITION

To scale or not to scale: the principles of dose extrapolation

(2009) Vijay Sharma et al.   BRITISH JOURNAL OF PHARMACOLOGY

Meropenem Pharmacokinetics, Pharmacodynamics, and Monte Carlo Simulation in the Neonate

(2008) John S. Bradley et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL